I-Mab to Present at 24th Annual Needham Virtual Healthcare Conference
I-Mab (NASDAQ: IMAB), a US-based global biotech company specializing in precision immuno-oncology treatments for cancer, has announced its upcoming participation in the 24th Annual Needham Virtual Healthcare Conference. The conference is scheduled to take place from April 7-10, 2025.
The company's management team will be present at this virtual healthcare event, which serves as a significant platform for biotechnology companies to showcase their developments and connect with industry stakeholders.
I-Mab (NASDAQ: IMAB), un'azienda biotecnologica globale con sede negli Stati Uniti specializzata in trattamenti di immuno-oncologia di precisione per il cancro, ha annunciato la sua prossima partecipazione alla 24ª Conferenza Virtuale Annuale di Needham sulla Salute. La conferenza si svolgerà dal 7 al 10 aprile 2025.
Il team di gestione dell'azienda sarà presente a questo evento virtuale sulla salute, che rappresenta una piattaforma significativa per le aziende biotecnologiche per mostrare i loro sviluppi e connettersi con gli attori del settore.
I-Mab (NASDAQ: IMAB), una empresa biotecnológica global con sede en EE. UU. especializada en tratamientos de inmuno-oncología de precisión para el cáncer, ha anunciado su próxima participación en la 24ª Conferencia Virtual Anual de Salud de Needham. La conferencia está programada para llevarse a cabo del 7 al 10 de abril de 2025.
El equipo de gestión de la empresa estará presente en este evento virtual de salud, que sirve como una plataforma significativa para que las empresas biotecnológicas muestren sus desarrollos y se conecten con los interesados de la industria.
I-Mab (NASDAQ: IMAB)는 미국에 본사를 둔 글로벌 생명공학 회사로, 암에 대한 정밀 면역항암제 치료를 전문으로 하며, 제24회 니드햄 가상 헬스케어 컨퍼런스에 참여할 예정이라고 발표했습니다. 이 컨퍼런스는 2025년 4월 7일부터 10일까지 개최될 예정입니다.
회사의 경영진 팀은 이 가상 헬스케어 이벤트에 참석할 예정이며, 이는 생명공학 회사들이 그들의 개발을 선보이고 업계 이해관계자들과 연결할 수 있는 중요한 플랫폼 역할을 합니다.
I-Mab (NASDAQ: IMAB), une entreprise biopharmaceutique mondiale basée aux États-Unis spécialisée dans les traitements d'immuno-oncologie de précision pour le cancer, a annoncé sa prochaine participation à la 24e Conférence Virtuelle Annuelle de Needham sur la Santé. La conférence est prévue du 7 au 10 avril 2025.
La direction de l'entreprise sera présente à cet événement virtuel de santé, qui constitue une plateforme importante pour les entreprises biopharmaceutiques afin de présenter leurs développements et de se connecter avec les acteurs de l'industrie.
I-Mab (NASDAQ: IMAB), ein globales Biotechnologieunternehmen mit Sitz in den USA, das sich auf präzise Immunonkologie-Behandlungen für Krebs spezialisiert hat, hat seine bevorstehende Teilnahme an der 24. jährlichen virtuellen Needham Healthcare-Konferenz angekündigt. Die Konferenz ist für den 7. bis 10. April 2025 geplant.
Das Management-Team des Unternehmens wird an diesem virtuellen Gesundheitsereignis teilnehmen, das eine bedeutende Plattform für Biotechnologieunternehmen darstellt, um ihre Entwicklungen zu präsentieren und sich mit Akteuren der Branche zu vernetzen.
- None.
- None.
ROCKVILLE, Md., March 26, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ: IMAB), a US-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer, today announced that I-Mab’s management team will participate in 24th Annual Needham Virtual Healthcare Conference, being held April 7-10, 2025.
Details are as follows:
| 24th Annual Needham Virtual Healthcare Conference | |
| Conference Date: | April 7-10, 2025 |
| Format: | Company Presentation and one-on-one meetings |
| Presentation Time: | Monday, April 7, 2025, 8:45 to 9:25 AM ET |
| Webcast Link: | Register here |
About I-Mab
I-Mab (NASDAQ: IMAB) is a US-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer. I-Mab has established operations in Rockville, Maryland, and Short Hills, New Jersey. For more information, please visit us at: https://www.i-mabbiopharma.com/ and follow us on LinkedIn and X.
I-Mab Investor & Media Contacts
PJ Kelleher
LifeSci Advisors
+1 617-430-7579
pkelleher@lifesciadvisors.com
IR@imabbio.com
FAQ
When is I-Mab (IMAB) presenting at the Needham Healthcare Conference 2025?
What type of company is I-Mab (IMAB) and what is their focus?
Is the Needham Healthcare Conference 2025 virtual or in-person?
Which stock exchange is I-Mab (IMAB) listed on?
